Conducting pharmacokinetic (PK) studies in pregnant women is challenging. Therefore, we asked if a physiologically based pharmacokinetic (PBPK) model could be used to evaluate different dosing regimens for pregnant women. We refined and verified our previously published pregnancy PBPK model by incorporating cytochrome P450 CYP1A2 suppression (based on caffeine PK) and CYP2D6 induction (based on metoprolol PK) into the model. This model accounts for gestational age-dependent changes in maternal physiology and hepatic CYP3A activity. For verification, the disposition of CYP1A2-metabolized drug theophylline (THEO) and CYP2D6-metabolized drugs paroxetine (PAR), dextromethorphan (DEX), and clonidine (CLO) during pregnancy was predicted. Our PBPK model successfully predicted THEO disposition during the third trimester (T 3 ). Predicted mean postpartum to third trimester (PP:T 3 ) ratios of THEO area under the curve (AUC), maximum plasma concentration, and minimum plasma concentration were 0.76, 0.95, and 0.66 versus observed values 0.75, 0.89, and 0.72, respectively. The predicted mean PAR steady-state plasma concentration (C ss ) ratio (PP:T 3 ) was 7.1 versus the observed value 3.7. Predicted mean DEX urinary ratio (UR) (PP:T 3 ) was 2.9 versus the observed value 1.9. Predicted mean CLO AUC ratio (PP:T 3 ) was 2.2 versus the observed value 1.7. Sensitivity analysis suggested that a 100% induction of CYP2D6 during T 3 was required to recover the observed PP:T 3 ratios of PAR C ss , DEX UR, and CLO AUC. Based on these data, it is prudent to conclude that the magnitude of hepatic CYP2D6 induction during T 3 ranges from 100 to 200%. Our PBPK model can predict the disposition of CYP1A2, 2D6, and 3A drugs during pregnancy.
Introduction
Pregnancy can affect the absorption (e.g., gastric pH, transporters), distribution (e.g., plasma protein binding and transporters), metabolism [e.g., cytochrome P450 (P450) metabolism], and excretion (e.g., renal secretion via transporters) (ADME) of drugs. Such changes can result in reduced efficacy (e.g., antiepileptics, antivirals) or increased toxicity of a drug. Considerable clinical data in the literature suggest that the magnitude of change in maternal hepatic enzyme activity, as reflected in the change in exposure to probe drugs, is P450 isoform-specific and gestational age-dependent (Hodge and Tracy, 2007) . Many of these studies have used model (probe) drugs that report P450 enzyme activities to delineate the magnitude of change in the activity of major P450 enzymes, mostly during the third trimester (e.g., caffeine for CYP1A2, metoprolol for CYP2D6, midazolam for CYP3A, and phenytoin for CYP2C9) (Anderson, 2005) .
Hepatic CYP1A2 enzyme activity, as measured by caffeine salivary clearance, is suppressed throughout pregnancy, with the greatest suppression of up to ;65% observed in the third trimester (T 3 ) versus postpartum (PP) (Tracy et al., 2005) . Consistent with these data, the oral clearance (CL ORAL ) of another CYP1A2 probe substrate, theophylline (THEO), is reduced by ;30% during T 3 versus PP, but the CL ORAL during the first (T 1 ) and second (T 2 ) trimesters is not affected (Gardner et al., 1987) . In contrast, the activity of hepatic CYP2D6 appears to be increased during pregnancy. In pregnant women, the mean CL ORAL of metoprolol (MET) (100 mg orally) during T 3 was almost 4-fold of that during postpartum (Hogstedt et al., 1985) . However, the i.v. clearance or the plasma protein binding of MET (10 mg) is not affected by pregnancy. Subsequently, two studies assessed CYP2D6 activity during pregnancy using the dextromethorphan/ dextrorphan (DEX/DXO) metabolic ratio in pregnant women. The plasma DEX/DXO metabolic ratio (2 hours post dose, ;T max ) during T 3 is significantly reduced (;2.3-fold PP:T 3 ) among extensive metabolizers (EMs), indicating increased CYP2D6 activity (Wadelius et al., 1997) . Similarly, the 24-hour DEX urinary metabolic ratio (UR: DEX/DXO) was significantly reduced throughout pregnancy in subjects phenotyped as EMs, with the greatest reduction (;1.9-fold PP:T 3 ) observed during T 3 (Tracy et al., 2005) . In accordance with the increased CYP2D6 activity during pregnancy, paroxetine (PAR) plasma concentrations steadily decrease over the course of pregnancy in women genotyped as CYP2D6 EMs (Ververs et al., 2009) . The most pronounced effect (73% reduction compared with postpartum) on PAR steady-state plasma concentrations is observed during T 3 . Finally, the CL ORAL of clonidine (CLO) is 1.7-fold of that in nonpregnant subjects (Buchanan et al., 2009 ). This increase in CLO CL ORAL is most likely due to increased CYP2D6 activity, as CYP2D6 plays a major role in in vitro CLO metabolism (Claessens et al., 2010) , and the renal clearance (CL r ) of clonidine appears not to be affected by pregnancy.
The above-described changes in P450 activities during pregnancy are postulated to reduce the efficacy or enhance the toxicity of drugs during pregnancy. Since it is logistically impossible to delineate the changes in the pharmacokinetics (PK) of all drugs administered to pregnant women, alternative approaches that can generalize across drugs and predict drug disposition in pregnancy are highly desirable. Physiologically based pharmacokinetic (PBPK) modeling has the advantage of incorporating both physiologic parameters that are important for ADME processes and drug-specific parameters (e.g., physicochemical and drug disposition characteristics) into a quantitative predictive model (Jamei et al., 2009; Rowland et al., 2011) . A maternal PBPK model incorporating known physiologic parameters as well as maternal hepatic P450 activity in each trimester was recently developed Gaohua et al., 2012; Lu et al., 2012) . We refined this PBPK model and showed that the PBPK model populated with CYP3A activity change, based on CL ORAL of midazolam, could accurately predict the T 3 disposition of other CYP3A-metabolized drugs, nifedipine and indinavir (Ke et al., 2012) . A sensitivity analysis suggested that CYP3A induction in T 3 is most likely hepatic and not intestinal. In the current study, we expanded and verified the established PBPK model by incorporating CYP1A2 suppression and CYP2D6 induction based on disposition of caffeine (Tracy et al., 2005) and metoprolol data (Hogstedt et al., 1985) . The model was then used to predict the disposition during pregnancy of CYP1A2-metabolized drug THEO, and CYP2D6-metabolized drugs PAR, DEX, and CLO.
Materials and Methods
General Workflow of PBPK Model Development and Verification Criterion. A general workflow of PBPK modeling and simulation of test compounds in nonpregnant subjects consisted of the following steps. First, mean plasma concentration-time profiles simulated using the Simcyp Population-based Simulator (version 11.1; Simcyp Limited, Sheffield, UK) were compared with those obtained from in vivo studies including i.v. dosing, single and multiple oral dosing. The 13-compartment full PBPK model was used. Second, the drug-specific parameters (e.g., f m ) underwent refinement (hence referred to as the modified model) if the prediction in the first step deviates significantly (,0.8-fold or .1.25-fold) from that observed. Such refinements were often based on changes in mean area under the curve (AUC) and mean concentration-time profiles in the presence of inhibitors or genetic polymorphism of the enzymes clearing the drug. Third, the time-varying full PBPK model constructed in Matlab version 7.10 (2010; Mathworks, Natick, MA) was populated with these qualified drug-specific parameters and pregnancyinduced P450 activity changes (see the following sections).
Verification of the established PBPK model was primarily based on AUC (for DEX data, urinary data were used as AUC data were not available) because achieving equivalent drug exposure in pregnant and nonpregnant women was our primary focus. The term "verification" is used in place of "validation" to acknowledge the complexity of the PBPK model that requires more than plasma data to accomplish proper validation. As secondary criteria, prediction of maximum plasma concentration (C max ) and minimum plasma concentration (C min ) was considered, because achieving similar drug C max and C min may be important for some drugs where these measures are related to drug efficacy and/ or toxicity. For model verification, 1) mean AUC, C max , and C min of THEO; 2) average steady-state concentration (C ss ) of PAR; 3) mean DEX/DXO UR; and 4) mean steady-state AUC of CLO during pregnancy were predicted and compared with published studies in pregnant, CYP2D6 EM subjects. We chose the criterion of PK bioequivalence as the criterion for successful verification of the model, namely, the predicted mean population PK parameters of the drug (as described earlier), should fall within 80-125% of the observed value, i.e., 0.80 # predicted/observed # 1.25.
General Pregnancy PBPK Model Structure and Key Assumptions. The general pregnancy PBPK model structure and key assumptions were described in detail previously (Gaohua et al., 2012; Ke et al., 2012) . Briefly, the gestational age-dependent changes in physiologic parameters (e.g., cardiac output, glomerular filtration rate, etc.) were incorporated into an existing PBPK scheme (Jamei et al., 2009) . Maternal glomerular filtration rate (GFR) was assumed to increase during pregnancy by 19, 40, and 37% during T 1 , T 2 , and T 3 , respectively . Renal secretion clearance mediated by organic cation transporter was assumed to increase by 50% during T 3 (metformin CL secretion ) . The fraction reabsorbed was assumed to remain constant through gestation. The change in drug unbound fraction in plasma (f u,p ) during pregnancy, as a function of serum albumin or a1-acid glycoprotein concentrations, was accounted for in the model as described previously (Ke et al., 2012) . The established PBPK model also assumed that hepatic CYP3A activity increased by 99% (measured by midazolam CL ORAL ) during T 3 (Ke et al., 2012) .
The PBPK model was further expanded to incorporate pregnancy-induced CYP1A2 suppression and CYP2D6 induction as described below. Maternal hepatic CYP1A2 was assumed to decrease during pregnancy by 33, 48, and 65% (salivary caffeine clearance) during the first (T 1 ), second (T 2 ), and third trimesters, respectively (Tracy et al., 2005) . Maternal CYP2D6 activity was assumed to increase by 200% (reported by metoprolol CL ORAL ) during T 3 (Hogstedt et al., 1985) . This value of 200% was obtained through sensitivity analysis by varying CYP2D6 activity in the range of 50-350% induction to recover the observed metoprolol data. Reliable assessment of the magnitude of CYP2D6 induction in earlier trimesters has not been conducted. All other maternal hepatic P450 activities were assumed to remain constant throughout pregnancy. These changes were accomplished in Matlab v7.10.
THEO PBPK Model Construction. THEO physiochemical and protein binding parameters [log P o:w (octanol-water partition coefficient), pK a , bloodto-plasma concentration ratio (B/P ratio)], absorption [fraction absorbed (F a ), intestinal bioavailability (F g )], and distribution [tissue-to-plasma partition coefficient (K p )] were obtained from Simcyp (version 11.1). Initial scaling of in vitro metabolic data to metabolic clearance (CL H ) overpredicted THEO CL H observed in vivo. Therefore, unbound intrinsic clearance (CL int,u ) was backcalculated from observed CL H using a well-stirred liver model. The contributions from individual CYPs to total metabolic clearance of THEO obtained in vitro were 91.7, 8, and 0.06% for 1A2, 2E1, and 3A, respectively (Tjia et al., 1996) . However, in vivo drug-drug interation studies using diltiazem and verapamil as the perpetrator (both are mechanism-based inactivators of CYP3A) reported an AUC percent change of 12-18% (Sirmans et al., 1988; Stringer et al., 1992) , suggesting that CYP3A plays a greater role in THEO metabolism in vivo. Therefore, the in vivo CYP1A2 contribution to total metabolic clearance was reduced to 80%, and in vivo CYP3A contribution was increased to 12%. The drug-dependent parameters of THEO are listed in Table 1 .
MET PBPK Model Construction. MET is mainly eliminated via hepatic metabolism (;84% by CYP2D6, ;7% by CYP3A4), with a minor contribution from renal elimination (;9%) (Brown et al., 2005; Ito et al., 2005) . After administration of a single dose of 100 mg in healthy volunteers, there is a 4.5-fold difference in the AUC of poor metabolizers (PMs) and EMs of CYP2D6 (Hamelin et al., 2000; Sharma et al., 2005) . MET physiochemical and protein binding parameters (log P o:w , pK a , B/P ratio, f u,p ), absorption [F a, F g, first-order absorption rate constant (k a )], distribution (K p ), and elimination (V max, K m,unbound ) were obtained from Simcyp (version 11.1). Initial scaling using in vitro V max determined in human liver microsomes significantly underpredicted CL IV in vivo i.v. clearance and CL ORAL by a factor of 2.2 and 2.3 in nonpregnant, CYP2D6 EMs. This underprediction was also evident in nonpregnant, CYP2D6 PMs (by a factor of 3.2 and 1.4 for CL IV and CL ORAL , respectively). To improve in vitro-in vivo extrapolation (IVIVE) prediction of CL H , in vivo V max for CYP2D6 and CYP3A4 was optimized by multiplying in vitro V max by a factor of 2 ( Table 2 ). The optimized drug model showed AUC, C max , and C min values following 100-mg single oral dosing in nonpregnant, CYP2D6 EM and PM subjects that were comparable to reported literature values. DDI prediction for the victim-perpetrator pair MET (100 mg SD orally) and quinidine (100 mg daily for 6 days) was evaluated to qualify drug-specific parameters, specifically f m,2D6 (fraction of total body clearance via CYP2D6).
The perpetrator drug model (quinidine, daily), readily available in Simcyp, was used in all simulations without modifications. The drug-dependent parameters of MET are listed in Table 2 .
PAR PBPK Model Construction. PAR is extensively metabolized in humans and exhibits nonlinear kinetics during single and multiple dosing (Kaye et al., 1989) . After the administration of a single dose of PAR, there is a 7-fold difference in the median total clearance in PMs and EMs of CYP2D6, which is then reduced to 2-fold at steady state (Sindrup et al., 1992a, b) . The nonlinear PK of PAR is much more pronounced in EMs than PMs, mainly due to timedependent inhibition of the CYP2D6-mediated metabolism (Venkatakrishnan and Obach, 2005) .
A previously published PAR PBPK model (Jornil et al., 2010) was modified as described later. Jornil et al. (2010) showed that, in addition to CYPs 2D6, 3A and 1A2 are involved in the metabolism of PAR. The authors then used prior in vitro and in vivo information on the metabolism of PAR to predict the exposure in EM and PM individuals receiving single and multiple dosing regimens using (Hendeles et al., 1985; St-Pierre et al., 1985) , and the mean value was used.
c Predicted from Caco-2 permeability of 25*10 26 cm/s (library) in Simcyp (version 11.1). d IR (immediate release): predicted from Caco-2 permeability of 25*10 26 cm/s (library) in Simcyp (version 11.1). SR (sustained release): estimated from reported t 1/2 ,a (absorption half-life) (Hendeles and Weinberger, 1983) . e Q gut model is provided in the Simcyp simulator. It retains the form of the "well stirred" liver model, but the flow term (Q gut ) is a hybrid of both permeability through the enterocyte membrane and villous blood flow (Yang et al., 2007) .
f Predicted according to Rodgers and Rowland (2007) . g Reported CL IV in nonpregnant, nonsmokers is 3.0 6 0.7 l/h (number of studies = 26) (University of Washington Drug Interaction Database, http://www.druginteractioninfo.org/).
h Calculated by taking the product of CL IV and reported mean f e . Reported f e ranges 13-18% (n = 22) in nonpregnant, nonsmoking healthy volunteers (Tang-Liu et al., 1982; St-Pierre et al., 1985) and 16.0% 6 3.3% (n = 5) in postpartum women (Frederiksen et al., 1986) following i.v. dosing. Weighted mean f e was used.
i Back calculation from well stirred liver model using Q H,B (hepatic blood flow) of 90 l/h. l The contribution from individual CYP obtained in vitro is 91.7, 8, and 0.06% for 1A2, 2E1, and 3A, respectively (Tjia et al., 1996) . However, in vivo drug-drug interaction studies using diltiazem and verapamil as the perpetrators (both are CYP3A mechanism-based inhibitors) reported an AUC percent change of 12-18% (Sirmans et al., 1988; Stringer et al., 1992) , suggesting that CYP3A played a greater role in THEO metabolism in vivo. Therefore, the contribution from individual CYP (80, 8, and 12% for 1A2, 2E1, and 3A, respectively) was adjusted accordingly. In vivo f m for individual P450 was calculated by taking the product of f m (1 2 f e ) and the contribution from individual P450. 
Predicted by Q gut model
Q gut , hybrid parameter of blood flow and drug permeability; V ss , volume of distribution at steady state.
a Refers to Simcyp compound library (version 11.1). b Predicted from human jejunum permeability (10 24 cm/s) (library data) in Simcyp (version 11.1).
c Not reported in the literature; predicted according to Rodgers and Rowland (2007) . d In vitro to in vivo extrapolation using in vitro V max and K m and average population values for liver weight and microsomal protein of 1618 g and 38.9 mg/g (liver), respectively. Reported CL IV in nonpregnant, CYP2D6 EMs and PMs is 72.5 6 32.2 l/h (range 48.6-93.2 l/h) (number of studies = 3, number of subjects = 28, male only) and 30.1 6 8.4 l/h (number of studies = 1, number of subjects = 3, male only) (University of Washington Drug Interaction Database, http:// www.druginteractioninfo.org/). Reported CL IV in postpartum women is 39 6 4.8 l/h (n = 5) (Hogstedt et al., 1985) .
e Reported mean value in nonpregnant, CYP2D6 EMs and PMs is 4.27 l/h (range 3.24-6.0 l/h) (number of studies = 6, number of subjects = 67) (University of Washington Drug Interaction Database, http://www.druginteractioninfo.org/).
f IVIVE (in vitro-in vivo extrapolation) approach using in vitro V max determined in human liver microsomes (provided in library) significantly underpredicted CL IV and CL ORAL by a factor of 2.2 and 2.3 in nonpregnant, CYP2D6 EMs. This underprediction was also evident in nonpregnant, CYP2D6 PMs (by a factor of 3.2 and 1.4, respectively). To improve IVIVE prediction of CL, in vivo V max for CYP2D6 and 3A4 was optimized by multiplying in vitro V max by a factor of 2. 
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Simcyp. However, the IVIVE approach significantly underpredicted singledose and steady-state median CL ORAL for CYP2D6 PM subjects by a factor of 2.9 and 3.5, respectively (Jornil et al., 2010) . It is worth noting that, even though PAR has been identified in vitro as a CYP3A mechanism-based inhibitor (Venkatakrishnan and Obach, 2005) , the in vivo importance of CYP3A inactivation by PAR may be limited (Jornil et al., 2010) . When such inactivation was considered, the predicted mean percentage of active CYP3A enzyme remaining at steady state was 97 and 93% in CYP2D6 EMs and PMs, respectively. In contrast, 34% of CYP2D6 activity was predicted to remain in EMs. Sensitivity analysis showed that varying the maximal inactivation rate constant (K inact,3A ) and inactivation constant (K I,unbound,3A ) in the range of 0.1-10-fold of reported values had minimal impact (,10%) on AUC and C max of PAR in the PM population, in which CYP3A is expected to be the major elimination pathway of PAR. Based on these analyses, it has been speculated that there is a non-CYP3A, nonrenal pathway responsible for PAR elimination in CYP2D6 PMs. Therefore, we modified the PBPK model established by Jornil et al. (2010) by incorporating an unidentified pathway (CL int , other ) (f m,other = 9.7% in CYP2D6 EMs) into the IVIVE model. The optimized drug model was verified by comparing the predicted mean AUC, C max , and C min following single or chronic oral dosing in nonpregnant, CYP2D6 EM and PM subjects to reported literature values. The drug-dependent parameters of PAR are listed in Table 3 . DEX and DXO PBPK Model Construction. The DEX/DXO metabolic ratio, such as plasma concentration of the parent/metabolite or UR, is commonly used in drug-drug interaction and pharmacogenetic studies as an in vivo measure of P450 2D6 activity (Borges et al., 2005; Lutz and Isoherranen, 2012) . DEX is extensively O-demethylated to dextrorphan by CYP2D6. The formation of DXO by CYP2D6 is responsible for approximately 97% of the oral clearance of DEX in EMs (Capon et al., 1996; Gorski et al., 2004) . Dextrorphan then undergoes glucuronidation mostly by UGT2B7 (Lutz and Isoherranen, 2012) . N-demethylation to 3-methoxymorphinan also occurs, largely by CYP3A4 (Yu and Haining, 2001 ). Both dextrorphan and 3-methoxymorphinan are further metabolized to 3-hydroxy-morphinan by CYP3A4 and 2D6, respectively (Yu and Haining, 2001; Lutz and Isoherranen, 2012) .
DEX physiochemical and protein binding parameters (log P o:w , pK a , B/P ratio, f u,p ), absorption (F a, F g ), distribution (K p ), and hepatic elimination (CYP3A-mediated unbound intrinsic clearance, or CL int,h,u,3A ) were from the Simcyp compound library (version 11.1). CL int,u,2D6 was estimated in Simcyp by simultaneously fitting observed plasma concentration-time profiles extracted from previous publications (Abdul Manap et al., 1999; Moghadamnia et al., 2003 ) (see Table 4 ). Optimization of CL int,u,2D6 was necessary to match predicted bioavailability (F a *F h *F g ;7%) to that reported (,5%) (Capon et al., 1996) . CL r of DEX was assumed to approximate f u,p *GFR (see footnote to Table 4 ). The optimized drug model was verified by comparing predicted mean AUC, C max , and C min values following single oral dosing, or in the presence of quinidine, in nonpregnant CYP2D6 EM and PM subjects to reported literature values.
Then, to predict the cumulative amount of DXO in urine, we constructed a semi-PBPK model with the following assumptions and/or simplifications: 1) the metabolite distributed homogeneously into nonmetabolic tissues/organs, and that these tissues can be combined into an apparent plasma compartment; 2) the metabolite formed in the gut and liver was available for further metabolism by CYP3A; and 3) glucuronidation of DXO was not incorporated due to lack of appropriate scaling factors for UGT enzymes in hepatic and extrahepatic tissues, therefore quantitative prediction of plasma concentrationtime profiles of free or total DXO was not possible. DXO physiochemical and protein binding parameters (log P o:w , pK a , f u,p ) and elimination (CYP3A-mediated unbound intrinsic clearance, or CL int,h,u,3A ) were obtained from the literature (Table 4) . Apparent CL r (5 l/h) of DXO was determined through sensitivity analysis by comparing simulated A e,DXO,0-24h (the cumulative amount of drug excreted into the urine during 0-24 hour interval) values to those reported (Jones et al., 1996; Abduljalil et al., 2010 ) (see footnotes to Table 4 ). Given the wide range of reported DXO recovery in urine [f e (fraction of total body clearance via renal excretion) = 40-91%], in addition to apparent CL r of DXO and CYP3A-mediated clearance, biliary excretion of DXO conjugates was incorporated into the DXO model (see footnote to Table 4 ). The combination that best recovered the observed A e,DXO was used in the final model. In addition, the DXO PBPK model accounted for pregnancy-induced changes including a decrease in plasma protein binding of DXO, an increase in apparent renal clearance of DXO, and an increase in CYP3A-mediated clearance of DXO. The drug-dependent parameters of DEX and DXO are listed in Table 4 .
CLO PBPK Model Construction. CLO has dose-proportional kinetics following i.v. administration and single or multiple dosing in the clinical dose range (Arndts et al., 1983) . In nonpregnant subjects, approximately 41-62% of orally administered CLO is cleared unchanged by the kidney (Frisk-Holmberg et al., 1981; Arndts et al., 1983) , with the remainder undergoing hepatic metabolism to produce inactive metabolites, mainly 4-hydroxyclonidine. Selective inhibition studies in human liver microsomes have shown that CYP2D6 plays a major role in clonidine metabolism, followed by CYP3A and 1A2 (Claessens et al., 2010) .
Physiochemical and protein binding parameters (log P o:w , pK a , f u,p ), absorption (F a, ), distribution (K p ), and elimination (CL IV, CL r, f e ) were obtained from the literature. B/P ratio and F g were predicted in Simcyp (version 11.1). The contribution from individual P450 to the metabolic clearance (67, 22, and 11% for CYP2D6, 3A, and 1A2, respectively) was obtained in human liver microsomes (Claessens et al., 2010) . Then, CL int,h,u for CYP2D6, 3A, and 1A2 were back-calculated from hepatic CL (CL-CL r ), f m for individual P450, and "average" population values for liver weight and hepatic P450 enzyme abundance for CYP3A, 1A2, and 2D6, respectively. The drug-dependent parameters of CLO are listed in Table 5 .
Results

Prediction of THEO PK in Pregnancy Using PBPK Model Incorporating CYP1A2 Suppression Based on Caffeine Data
The disposition of THEO following multiple PO doses during T 3 and PP was predicted (Gardner et al., 1987) . Briefly, the disposition of THEO was assessed in 10 pregnant, nonsmoking asthmatic women who had been continuously maintained on sustained-release theophylline. Twenty-four hours preceding the study, all subjects were switched to immediate-release theophylline tablets, and the last dose was given before midnight of the study day. After overnight fasting, a single oral dose of theophylline (Somophyllin liquid, 259 mg) was administered. Compared with PP (range of 14-58 weeks PP), THEO CL ORAL during T 1 (13-19 weeks) and T 2 (23-28 weeks) was not significantly altered. THEO CL ORAL during T 3 (range of 34-39 weeks) was reduced and remained suppressed during the immediate PP period (9-13 weeks PP) (Gardner et al., 1987) . Hence, systemic exposures of THEO obtained during 14-58 weeks PP were considered to represent baseline levels, and those obtained during the immediate PP period (9-13 weeks PP) were excluded. The predicted mean THEO AUC ratio (AUCR) (PP:T 3 ), C max ratio (PP:T 3 ), and C min ratio (PP:T 3 ) were 0.76, 0.95, and 0.66, compared with the observed values of 0.75, 0.89, and 0.72, respectively ( Fig. 1; Supplemental Table 1 ). All predictions met the verification criterion (i.e., the predicted/observed of mean AUC, C max , and C min were in the range of 0.9-1.1). Predicted mean THEO AUCRs for PP:T 1 and PP:T 2 were 0.79 and 0.77, compared with observed values of 0.99 and 0.95, respectively (Supplemental Table 1 ). THEO plasma unbound fraction was predicted to be modestly increased from 58% during postpartum to 66% in T 3 , consistent with observed values (59% PP versus 68% T 3 ). THEO CL r was predicted to be increased from 0.45 l/h during postpartum to 0.68 l/h in T 3 , a 52% increase that is comparable to the observed 48% reported by Frederiksen et al. (1986) . Table 2 ). Specifically, the predicted AUC PM/EM ratio of 4.1 matched well with the observed ratio of 4.5 (Hamelin et al., 2000; Sharma et al., 2005) . The predicted mean AUC I (the plasma AUC in the presence of an inhibitor)/AUC for victim-perpetrator pair MET (100 mg single oral dose) and quinidine (100 mg daily for 6 days) is 3.3-fold, compared with the observed AUCR of 3.2-fold (Johnson and Burlew, 1996) . The corresponding predicted/observed of mean C max and C min were in the range of 0.7-0.9 and 1.3-1.4, respectively.
MET exposure in pregnant women was assessed (Hogstedt et al., 1985) , and the observed increase in CL ORAL, during pregnancy, was used to deconvolute the magnitude of increase in CYP2D6 activity after accounting for other pregnancy-related components of MET CL ORAL (CYP3A-mediated CL, CL r and protein binding). In this study, the disposition of MET following i.v. and oral dosing was studied in five women who developed hypertension during pregnancy and after delivery. The change in systemic clearance following i.v. dosing of MET (10 mg) during pregnancy versus postpartum was insignificant, although there was a trend toward higher CL IV during T 3 (T 3 versus PP: 82.8 6 15.6 versus 39 6 4.8 l/h; n = 5). The mean CL ORAL following a single oral dose of 100 mg during pregnancy was almost quadrupled (range: 2-13-fold). Although the CYP2D6 genotype of the five study subjects was not determined, comparison of reported individual AUC values following oral dosing to literature values (Johnson and Burlew, 1996; Hamelin et al., 2000; Sharma et al., 2005) confirmed that the systemic exposures of all five subjects were comparable to those of EM subjects and were significantly lower than those of PM subjects (Hamelin et al., 2000; Sharma et al., 2005) (Fig. 2A) . The PBPK model incorporating 200% induction of CYP2D6 during T 3 predicted a mean AUCR (PP:T 3 ) of 3.0, mean C max ratio (PP:T 3 ) of 2.8, and mean C min ratio (PP:T 3 ) of 3.5 compared with the observed ratios of 3.6 6 2.3, 2.4 6 1.3, and 2.0 6 2.5, 9.6 f m,other 9.7
Q gut , hybrid parameter of blood flow and drug permeability; V ss , volume of distribution at steady state. a Predicted from Caco-2 permeability of 17*10 26 cm/s (Jornil et al., 2010) in Simcyp (version 11.1). b V ss was not reported in the literature. The predicted V ss according to Rodgers and Rowland (2007) is 7.5 l/kg. This value was further optimized to 12.95 l/kg by applying a global K p scalar of 1.7, to improve prediction of C max . Reported V d following i.v. infusion is 17.2 6 9.9 l/kg (range 8.0-28.0) (Kaye et al., 1989) .
c Simcyp-predicted CL in CYP2D6 EM individuals via IVIVE is 80.7 6 13.8 l/h (n = 100). Reported CL is 74.9 6 14 l/h (range 63-91.7, n = 4) following 23-28 mg i.v. over 30 minutes (Kaye et al., 1989) . The genotype of these subjects was not determined.
d In CYP2D6 PM subjects, both single-dose and steady-state median CL oral were significantly underpredicted by a factor of 2.9 and 3.5, respectively, using the IVIVE approach (Jornil et al., 2010) . To match single-dose and steady-state CL oral in P450 2D6 PMs, an unidentified pathway (CL int , other ) was incorporated into the IVIVE model. e f m is dose-and time-dependent. Following 20 mg single-dose (n = 100 subjects), the predicted time-averaged mean f m is 94.3% (2D6), 2.8% (3A4), 0.1% (1A2), 0.1% (2C19), and 2.7% (unidentified CL), respectively, in EMs. Following 20 mg daily (n = 100 subjects), the predicted time-averaged mean f m at steady-state is 80% (2D6), 9.6% (3A4), 0.5% (1A2), 0.2% (2C19), and 9.7% (unidentified CL), respectively, in EMs. In CYP2D6 PMs, the predicted time-averaged mean f m is similar following 20 mg single-dose versus 20 mg daily: 48.5% (3A4), 2.6% (1A2), 1.1% (2C19), and 47.5% (unidentified CL) versus 46.9% (3A4), 2.7% (1A2), 1.1% (2C19), and 49.0% (unidentified CL).
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at ASPET Journals on April 20, 2017 dmd.aspetjournals.org Downloaded from respectively (Fig. 2B) . With the exception of the C min ratio, the modelpredicted AUCR and C max ratio met the verification criterion (Supplemental Table 2 ). The predicted MET plasma unbound fraction was 88% during PP versus 90.7% in T 3 , consistent with the observed values (89% 6 11% PP versus 90.7% 6 17% T 3 ).
PAR PK Prediction in Pregnancy. We modified a previously published PAR PBPK model (see Materials and Methods) and predicted single-dose (SD; 30 mg) and steady-state (SS; 30 mg daily) PAR AUC in both EM and PM nonpregnant individuals. The mean AUC 0-inf (plasma AUC extrapolated to infinity) or AUC ss,0-tau [plasma AUC over the dosing interval (tau) at steady state] in nonpregnant, CYP2D6 EM and PM subjects was quantitatively predicted by the modified PAR model (i.e., predicted/observed in the range of 0.8-1.2) ( Fig. 3A ; Supplemental Table 3 ). The model-predicted mean SD and SS C max and C min in EMs met the verification criterion. In PMs, the predicted/observed values of mean SD and SS C max and C min were in the range of 1.0-1.3 (Supplemental Table 3 ). PAR exposure in pregnant women was predicted based on the study design described by Ververs et al. (2009) . In this study, subjects were genotyped, and steady-state (C ss,ave ) PAR plasma concentrations were examined in each of the three trimesters but not postpartum. Women who were genotyped as EM showed steadily decreasing plasma paroxetine concentrations during the course of pregnancy. During T 3 , the median C ss,ave plasma concentration declined to 5 ng/ml (range 0.6-19.6 ng/ml) following the daily dose of 19.9 6 8.8 mg (range 3-40 mg), compared with the median C ss,ave plasma concentration of 18.4 ng/ml (range 3.3-66 ng/ml) in historical controls receiving 20 mg daily (Sindrup et al., 1992a) . These observations correspond to a median C ss,ave ratio (PP:T 3 ) of 3.7 (Fig. 3B ). The PBPK model incorporating 200% induction of CYP2D6 during T 3 predicted a mean PAR C ss,ave ratio (PP:T 3 ) of 7.1 following 20 mg daily (14 days). Sensitivity analysis suggested that a 100% induction of CYP2D6 during T 3 was required to recover the observed change in PAR C ss,ave ratio (PP:T 3 ) (predicted value 4.1) ( Fig. 3B ; Supplemental Table 4 ). Furthermore, CYP2D6 activity was induced modestly by 10 and 25% in T 1 and T 2 , respectively, to recover the observed changes in median PAR C ss ratios PP: T 1 and PP:T 2 of 1.6 and 1.9, respectively (unpublished data) .
DEX PBPK Model Prediction. The modified (see Materials and Methods) DEX model-predicted mean AUC in nonpregnant, CYP2D6 EM and PM subjects following the administration of a single oral dose of 30 mg DEX met the verification criterion (i.e., predicted/observed values within the range of 0.9-1.0) (Fig. 4 ; Supplemental Table 5 ). Kanaan et al. (2008) . d Reported in Lutz and Isoherranen (2012) . e Not reported in the literature; predicted according to Rodgers and Rowland (2007) . f Calculated mean value of reported V d in the literature: range of 300-650 l or 4.3-9.3 l/kg (assumed body weight = 70 kg) (Albers et al., 1995) .
g Calculated mean DXO CL app (dose*f m,2D6 /AUC DXO ) was 12.5 l/h. Dose and AUC DXO (free + conjugated drug) were taken from Capon et al. (1996) , Abdul Manap et al. (1999) , and Gorski et al. (2004) .
h Reported medians and ranges for CL r of DEX: 9.0 l/h (1.4-37 l/h) for extensive metabolizers (Capon et al., 1996) . Model-estimated CL r were 6.5 l/h (Abduljalil et al., 2010 ) and 3 l/h (Moghadamnia et al., 2003) . Given the substantial variability in literature values, CL r of DEX was assumed to approximate f u , p *GFR.
i Calculated CL r = Ae, DXO /AUC DXO was in the range of 5-12 l/h. A e,DXO (free + conjugated drug) was calculated by dose * percentage urinary recovery (reported range 40-91%), and AUC DXO (free + conjugated drug) was taken from Capon et al. (1996) ; Abdul Manap et al. (1999); and Gorski et al. (2004) . A sensitivity analysis on apparent CL r of DXO in the range of 5-12 l/h was conducted, and the final value (5 l/h) was selected based on predicted A e,DXO,0-24h being the closest match to observed A e,DXO in the literature (Abduljalil et al., 2010) (Fig. 5A ). This CL r corresponds to a urinary recovery of 40%. A higher percentage urinary recovery overpredicted A e,DXO .
j CL int,u,2D6 was estimated in Simcyp by simultaneously fitting observed plasma concentration-time profiles extracted from Abdul Manap et al. (1999) and Moghadamnia et al. (2003) using an initial estimate of 253.0 (ml/min/mg) provided in a compound library. CL int,u,3A was provided in a compound library.
k Taken from Lutz and Isoherranen (2012) . l Back calculation from biliary CL (CL app -CL m,3A -CL r ) and average population values for liver weight and hepatocellularity of 1618 g and 117.5 (millions of cells/g liver), respectively. m Reported f m,2D6 = 97% (Capon et al., 1996; Gorski et al., 2004) .
Specifically, the predicted AUC PM/EM ratio of 65.0 was comparable to the observed ratio of 73.5 (predicted/observed ratio of 0.9). In addition, the predicted mean AUC I /AUC for the victim-perpetrator pair DEX (30 mg single oral dose) and quinidine (50 mg single oral dose given 1 hour prior to the DEX dose) was 15.9-fold, compared with an observed mean AUC I /AUC of 20.8-fold (predicted/observed ratio of 0.8) (Capon et al., 1996; Abdul Manap et al., 1999) . The modelpredicted mean C max in the presence/absence of quinidine in nonpregnant, CYP2D6 EMs met the verification criterion (i.e., predicted/ observed values within the range of 0.9-1.1) ( Fig. 4 ; Supplemental Table 5 ). The mean C max in nonpregnant, CYP2D6 PMs was slightly overpredicted (predicted/observed of 1.3). The mean C min in the presence and absence of quinidine in nonpregnant, CYP2D6 EMs was underpredicted (predicted/observed of 0.2 and 0.5, respectively). However, model-predicted mean C min in nonpregnant, CYP2D6 PMs met the verification criterion (predicted/observed of 0.8). Furthermore, the predicted mean cumulative amount (0.06 mg) of DEX (30 mg orally) excreted in urine (A e,0-24h ) in EMs was also in reasonable agreement with the observed data: 0.075 6 0.167 mg (Abduljalil et al., 2010) and 0.153 6 0.155 mg (Jones et al., 1996) (Fig. 5A ).
Since plasma concentration-time data for DEX are not available in pregnant subjects, a semi-PBPK model to predict the cumulative amount of DXO excreted in urine was constructed (see Materials and Methods). The model-predicted A e,0-24h of DXO in EMs, following the administration of a single oral dose of 30 mg, was within the range of the observed values (9.6 mg predicted versus 1.3-15.3 mg observed) (Jones et al., 1996; Abduljalil et al., 2010) (Fig. 5A) . Further, the predicted PP UR 0-24h (0-24 hour urinary ratio) (DEX/ DXO) of 0.0065 in 2D6 EMs matched the reported median PP UR 0-24h of 0.0063 [90% confidence interval (CI): 0.0037-0.027; n = 25) (Tracy et al., 2005) and the reported UR 0-72h (mean: 0.0082; range: 0.0007-0.028) in nonpregnant, CYP2D6 EMs (n = 11) (Borges et al., 2005) . The observed median T 3 DEX UR 0-24h was 0.0033 (90% CI: 0.0015-0.0086), compared with the median PP DEX UR 0-24h of 0.0063 (90% CI: 0.0037-0.027). These observations correspond to a median DEX UR (PP:T 3 ) of 1.9 6 1.2. The PBPK model incorporating 200% induction of CYP2D6 during T 3 predicted a mean DEX UR (PP:T 3 ) of 2.9. Sensitivity analysis by varying CYP2D6 activity in the range of 50-250% suggested that a 100% induction of CYP2D6 during T 3 was required to recover the observed change in DEX UR (predicted value 1.9) ( Fig. 5B ; Supplemental Table 6 ). The reported median DEX UR PP:T 1 and PP:T 2 is 1.6 and 1.9, respectively, suggesting the magnitudes of CYP2D6 induction during T 1 and T 2 are similar to that of T 3 .
CLO PBPK Model Prediction. The constructed CLO PBPK model was first verified by comparing the predicted versus the observed disposition kinetics of an i.v. dose of 1.79-2.35 mg/kg to nonpregnant healthy volunteers (Frisk-Holmberg et al., 1981) . The predicted/observed AUC 0-inf was in the range of 1.1-1.2 (Supplemental Table 7 ). The predicted/observed C min, 24h (minimum plasma concentration sampled at 24 hours post-dose) was 0.4 (2.35 mg/kg) and 1.0 (1.79 g/kg). The PBPK model was also verified against the disposition kinetics following the administration of a single oral dose of 0.1-0.3 mg to nonpregnant healthy volunteers. Model-predicted AUC 0-inf, C max , and C min, 24h all met the verification criterion ( Fig. 6A ; Supplemental Table 7 ). The PBPK model incorporating 200% induction of CYP2D6 during T 3 predicted a mean AUCR (PP:T 3 ) of 2.2 (observed value 1.7) (Buchanan et al., 2009 ). Sensitivity analysis suggested that a 100% induction of CYP2D6 during T 3 better recovered the observed AUCR (PP:T 3 ) (predicted value 1.8) ( Fig. 6B ; Supplemental Table 8 ). Because clonidine is a substrate of renal transporter organic cation transporter, the current PBPK model accounted for a pregnancy-induced increase in GFR and OCTmediated secretion (measured by metformin CL secretion ) Higgins et al., 2012) , and predicted that CLO CL r increased from 116.8 ml/min to 182.7 ml/min. If CL r was kept constant during T 3, both 100 and 200% induction of CYP2D6 during T 3 (1.48 and 1.84, respectively; Supplemental Table 8 ) could recover the observed AUCR (PP:T 3 ) of 1.7.
Discussion
The pregnancy PBPK model populated with CYP1A2 activity change based on caffeine salivary clearance quantitatively predicted THEO disposition during T 3 . The pregnancy effect on THEO is smaller than the decrease in CYP1A2 activity (reported by caffeine data), as THEO has significant renal clearance (15%) and minor CYP3A-mediated clearance (7%), both of which increase during T 3 , and counteracts the decrease in 1A2 activity. Based on the 1A2 decrease during T 1 and T 2 reported by the caffeine data, a modest increase (,23%) in THEO AUC during T 1 and T 2 was predicted. Such a modest decrease may not be detectable in the clinic or be Q gut , hybrid parameter of blood flow and drug permeability; V ss , volume of distribution at steady state.
a Hardman et al. (2001) . b Reported in Ghasemi and Saaidpour (2007) . c Reported in Cody and DeTitta (1979) . d Predicted using physicochemical parameters in Simcyp. Reported B/P ratio in rodents is 1.07 (Yamahata et al., 1996) .
e Reported in Vanholder et al. (1988) and Boehringer Ingelheim (2011). f Mean reported bioavailability is 92% (range 88-96%) following a single oral dose of clonidine (Frisk-Holmberg et al., 1981; Arndts et al., 1983) . Simcyp-predicted F h is 0.95 and F g is 0.99, therefore calculated F a is 0.98.
g Reported in Frisk-Holmberg et al. (1981); Anavekar et al. (1982); and Porchet et al. (1992) . h Predicted according to Rodgers and Rowland (2007) ; estimated V ss value from i.v. dosing profiles is ;3 l/kg (Frisk-Holmberg et al., 1981) . Mean K p values determined in rodents (Conway and Jarrott, 1980; Yamahata et al., 1996) were used, as opposed to predicted K p values, because these values were found to better characterize the biphasic distribution of clonidine in plasma following either i.v. or oral dosing.
i Mean of reported values (Frisk-Holmberg et al., 1981; Arndts et al., 1983) . j Calculated by taking the product of CL IV and reported mean f e (Frisk-Holmberg et al., 1981; Arndts et al., 1983; Buchanan et al., 2009) .
k Back calculation from hepatic CL (CL -CL r ), f m for individual P450 (see next footnote), and average population values for liver weight and hepatic P450 enzyme abundance of 137, 52, and 8 pmol/mg protein for CYP3A, 1A2, and 2D6, respectively. l Reported f m for individual P450 was calculated by taking the product of f m (i.e., 1 -f e ) and the contribution from individual CYPs (67, 22, and 11% for 2D6, 3A, and 1A2, respectively) obtained in human liver microsomes (Claessens et al., 2010) .
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The increase in CYP2D6 activity during pregnancy is intriguing because 2D6 is not inducible by xenobiotics, and only hepatocyte nuclear factor-4a has been shown to have a role in regulating 2D6 transcription (Corchero et al., 2001) . Given that MET has linear PK and is a well accepted 2D6 probe drug (f m,2D6 = 84%) with minor involvement from other clearance pathways (CYP3A-mediated CL and CL r ), the pregnancy PBPK model was populated with 2D6 activity change based on CL ORAL of MET. The lack of significant pregnancy-induced effect following i.v. dosing is not surprising. MET is an intermediate-to-high extraction ratio drug, and CL IV is reflective of both the magnitude of hepatic blood flow and 2D6-mediated intrinsic clearance. The lack of pregnancy-induced effect on CL IV suggests that hepatic blood flow does not increase significantly during T 3 . This is consistent with the conclusion drawn from a meta-analysis of literature data on the direct assessment of hepatic blood flow in pregnant women .
Because in vitro PAR metabolic data did not recover observed metabolic clearance in nonpregnant EM and PM individuals, we modified a published PAR model by incorporating an unidentified pathway (CL int , other ) into the IVIVE model. At steady state (20 mg daily), this CL int , other contributes ,10% of PAR clearance in EMs and ;50% in PMs (see Table 3 ). CL int , other was assumed not to be affected (Gardner et al., 1987) . Error bars represent standard deviations. Conc., concentration. (Hamelin et al., 2000; Sharma et al., 2005) are overlaid, as are the mean observed data in postpartum women (s) (Hogstedt et al., 1985) . (B) Predicted and observed plasma concentration-time profiles of MET (100 mg orally) during T 3 and PP. The solid line represents the predicted mean postpartum profile. The dashed line represents the predicted mean T 3 profile. The mean observed data are overlaid (d, postpartum profile; s, T 3 profile) (Hogstedt et al., 1985) . Error bars represent standard deviations. Conc., concentration.
by pregnancy. Under this assumption, the magnitude of 2D6 induction would be slightly overestimated by assuming this CL int , other pathway is not induced. However, if the contrary is true and CL int , other is suppressed (more likely; see below), the impact of this minor pathway on estimating the magnitude of CYP2D6 induction would be minimal in 2D6 EMs (,10%). A 2D6 induction of 100%, as opposed to 200%, recovered the observed C ss (PP:T 3 ) in EMs. Interestingly, in PMs, the median PAR C ss was 48, 65, and 71 mg/l during T 1 , T 2 , and T 3 , respectively (n = 2) (Ververs et al., 2009) . In comparison, the reported C ss in nonpregnant PMs is 80 6 16 mg/l (n = 3) (Sindrup et al., 1992a) . From this very limited data set, we speculate that, in PMs where CL int , other and CYP3A contribute equally to PAR clearance, CL int , other is suppressed during pregnancy, similar to 1A2. This suppression counteracts the effect of CYP3A induction.
DEX is the most sensitive CYP2D6 probe substrate with the highest f m,2D6 among all the drugs included in the model verification set. Therefore, we would expect the systemic exposure of DEX to be reduced substantially in pregnant women. However, such evaluation of DEX plasma concentration-time profiles in pregnant women is not available in literature. Nonetheless, Wadelius et al. (1997) reported a change in DEX plasma concentration (2 hours post dose, ; T max ) of 2.3-fold (PP:T 3 , range 1.5-4.9-fold) in CYP2D6 EMs (n = 13). Despite the expected variability associated with C max , this change in DEX concentration is in line with ;100% induction of 2D6: modelpredicted DEX AUCR (PP:T 3 ) and C max (PP:T 3 ) were 2.4 and 3.0 in 2D6 EMs (unpublished data). A 200% induction of 2D6 would overpredict C max (PP:T 3 ) by 91%.
Since the pregnancy effect on DEX UR 0-24h was evaluated, we developed a semi-PBPK model of DXO to predict this UR. Construction of a fully mechanistic DXO model is not possible, mainly because once DXO is formed by CYP2D6, significant glucuronidation of DXO in hepatic and extrahepatic tissues occurs, and the appropriate scaler for IVIVE of this clearance is not available (Lutz and Isoherranen, 2012) . However, this limitation is not expected to impact (Sindrup et al., 1992b) . (B) Predicted and observed steady-state (C ss ) PAR plasma concentrations following 20 mg daily during T 3 and PP. The gray bars represent predicted C ss and C ss ratio (PP:T 3 ) assuming 200% induction (Ind.) of CYP2D6, and the black bars represent predicted C ss and C ss ratio (PP:T 3 ) assuming 100% induction of CYP2D6. The white bars represent observed median C ss in nonpregnant historical controls (Sindrup et al., 1992b) , in pregnant women during T 3 (Ververs et al., 2009) , and calculated C ss ratio (PP:T 3 ) based on observed median C ss .
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at ASPET Journals on April 20, 2017 dmd.aspetjournals.org our ability to predict DEX UR 0-24h , as the latter is based on the total DXO amount excreted in urine, and free and conjugated DXO are mostly recovered in urine (range of recovery 40.2-85%) (RostamiHodjegan et al., 1999 ). The developed model quantitatively predicted mean A e,DEX, A e,DXO , and mean DEX UR 0-24h in nonpregnant, 2D6 EMs. It is important to note that the interindividual and interstudy variability in observed A e,DEX and A e,DXO in nonpregnant, 2D6 EMs is substantial, possibly due to the heterogeneity of the 2D6 EM population (i.e., allelic variant-specific 2D6 activity) and urine pH dependency of DEX CL r (Abduljalil et al., 2010 ). The PBPK model incorporating 200% induction of CYP2D6 during T 3 overpredicted mean DEX UR (PP:T 3 ) by 50%. To recover the observed change, 2D6 activity would need to be induced less than 200%, or the CL r of DEX would need to be increased by 2.5-fold. In the current PBPK model, DEX CL r is assumed to be mainly filtration clearance, as DEX has not been identified as a substrate of major renal transporters. Recent evidence suggests DEX Manap et al., 1999; ♦, Gorski et al., 2004; m, Abduljalil et al., 2010 ) and PMs (s, Capon et al., 1996; ◊, Gorski et al., 2004) are overlaid. The mean observed data (+, X) in nonpregnant EMs in the presence of quinidine are overlaid (+, Abdul Manap et al., 1999; X, Capon et al., 1996) . Conc., concentration. Jones et al., 1996; d, Abduljalil et al., 2010) and DXO (◊, Jones et al., 1996; ♦, Abduljalil et al., 2010) may be secreted by the kidneys (unpublished data, J. D. Lutz and N. Isoherranen). Nevertheless, until confirmed, we concluded that 100% induction of CYP2D6 during T 3 was required to recover the observed change in DEX UR.
In pregnant women, CL r (153 6 67 ml/min) of CLO (Buchanan et al., 2009 ) did not deviate significantly from that obtained in a Japanese male population (183 6 55 ml/min) (Fujimura et al., 1994) . Therefore, the authors attributed the increase in apparent oral clearance of clonidine during pregnancy to a change in its nonrenal clearance (i.e., CYP2D6). On closer examination, the reported CL r in pregnant women is higher than calculated CL r (f e *CL IV ) based on mean f e and mean CL IV in the literature (116.8 ml/min; see Table 5 ). Nevertheless, if CL r was kept constant during T 3, both 100 and 200% induction of 2D6 during T 3 could recover the observed AUCR (PP: T 3 ). This finding is not surprising, because CLO AUCR (PP:T 3 ) is not a sensitive reporter of changes in CYP2D6 activity (f m,2D6 = 30%) when the latter is masked by a change or lack of change in CL r , the major elimination pathway of CLO (f e = 41-62%) (ZamekGliszczynski et al., 2009) .
The previous analyses suggest that CYP2D6 induction during pregnancy could range from 100 to 200%. To determine if this range could be narrowed, we expanded our sensitivity analysis to recover a possible range of 2D6 induction that brackets 80-125% of the observed MET, PAR, DEX, and CLO data in pregnancy. We found these ranges did not overlap, indicating the drugs evaluated reported a different magnitude of CYP2D6 induction, even after accounting for interstudy variability. The reason for these discrepancies is not clear, although we suspect it may be related to the study design being less than optimal. For example, the MET study has a limited sample size, and the interindividual variability of the observed data is large; the PAR dose used varied from 3 to 40 mg in the PAR study, and the reported PAR concentrations normalized to the mean dose of 20 mg can be misleading for a drug with nonlinear kinetics. Additional limitations include the lack of concentration-time profile (PAR and DEX) or the use of urinary metabolic ratio as an index of enzyme activity (DEX) in the published reports. Therefore, to definitively assess the magnitude of CYP2D6 induction during pregnancy, we propose that a PK study with the most sensitive 2D6 probe DEX, where the plasma concentration-time profile of DEX is measured, be conducted during various stages of pregnancy and postpartum. In the absence of such data, we can only conclude that the CYP2D6 induction during the third trimester ranges from 100 to 200%.
The underlying mechanism for the hepatic isoform-specific and gestational state-specific induction during pregnancy is not fully understood. Data from human hepatocyte incubation with pregnancyrelated hormones suggest that the rising concentrations of various hormones in maternal blood, including placental growth hormone, progesterone, corticosteroids, and estrogens, contributes to induction of some of these isoforms (Jeong, 2010; Dickmann and Isoherranen, 2013) . In contrast, suppression of CYP1A2 activity during pregnancy may be due to the increase in circulating concentration of cytokines (e.g., interleukin-1b and interleukin-6), which suppress 1A2 mRNA expression in human hepatocytes (Dickmann et al., 2011) . However, the mechanisms for CYP2D6 induction during pregnancy still remain unknown, and further mechanistic studies are warranted to fill this knowledge gap.
In summary, we have 1) shown that our PBPK model can quantitatively predict the disposition of the CYP1A2 drug THEO during T 3 ; 2) defined the range of 2D6 induction during T 3 to be 100-200% through modeling MET, PAR, DEX, and CLO disposition during pregnancy; and 3) shown that our PBPK model allows extrapolation beyond model drugs studied (e.g., caffeine and metoprolol) to other drugs with well characterized ADME characteristics (e.g., THEO, PAR). Previously, we have shown that such extrapolation can also be made for CYP3A-metabolized drugs (Ke et al., 2012) . Our study also highlights the importance of further mechanistic and probe drug studies pertaining to CYP2D6 induction during pregnancy. Since conducting PK studies in pregnant women is challenging, we propose that this refined PBPK model be used to evaluate different dosing regimens of CYP3A4-, 1A2-, and 2D6-metabolized drugs during pregnancy. (Porchet et al., 1992) ; black filled circles: observed data (0.3 mg) (Cunningham et al., 1994) . ( 
